Becker's Healthcare June 18, 2024
Erica Carbajal

On June 17, Merck received FDA approval for a vaccine designed to protect adults from pneumococcus, a type of bacteria that can cause serious disease, including pneumonia.

The conjugate vaccine, called Capvaxive, is meant to protect against 21 strains of the bacteria that most often cause invasive pneumococcal disease in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article